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dbstract
A novel oral controlled delivery system for propranolol hydrochloride (PPL) was developed and optimized. The in vitro dissolution profiles of
ustained-release matrix tablets of racemic PPL were determined and compared with the United States Pharmacopeia (USP) tolerance specifications
or Propranolol Hydrochloride Extended-Release Capsules. The influence of matrix forming agents (native dextran, hydroxypropyl methylcellulose
HPMC), cetyl alcohol) and binary mixtures of them on PPL release in vitro was investigated. A central composite design was applied to the
ptimization of a sustained-release tablet formulation. The sustained-release matrix tablets with good physical, mechanical and technological
roperties were obtained with a matrix excipient:PPL ratio of 60:40 (w/w), with a dextran:HPMC ratio of 4:1 (w/w) and with a cetyl alcohol
mount of 15% (w/w). A comparative kinetic study of the present matrix tablets and commercial SUMIAL RETARD capsules (Spain) was
stablished. The value for the similarity factor (f2 = 69.6) suggested that the dissolution profile of the present two sustained-release oral dosage
orms are similar. Higuchi (diffusion) and Hixon–Crowell (erosion) kinetic profiles were achieved and this codependent mechanism of drug release
as established.
eywords: Native dextran; Sustained release; Optimization; Propranolol; Tablets
. Introduction
Propranolol hydrochloride (PPL) is a -adrenergic blocking
gent, i.e. a competitive inhibitor of the effects of catecholamines
t -adrenergic receptor sites. It is widely used in therapeutics
or its antihypertensive, antiangorous and antiarrhythmic prop-
rties. Furthermore, it has a short elimination half-life of 3 h,
hich makes it a suitable candidate to be delivered at a con-
rolled rate (Kwong et al., 1988).
Controlled release dosage forms improve patient compliance
nd decrease incidences of adverse drug reactions. Ideally, a
ontrolled release dosage form will provide therapeutic concen-
∗ Corresponding author. Tel.: +53 7 271 3994; fax: +53 7 273 6471.
E-mail address: eddy02cu@yahoo.es (E.C. Gil).
tration of the drug in the blood that is maintained throughout the
dosing interval with a reduction in the peak/nadir concentration
ratio (Yacobi and Walega, 1988). Hydrogels have attracted
considerable attention in recent years as controlled release
devices for the delivery of water-soluble drugs (Woodford
and Hsieh, 1988). Hydroxypropyl methylcellulose has been
employed extensively as hydrophilic matrix former in oral
controlled-release dosage forms for different drugs including
propranolol. Its popularity can be attributed to the polymer’s
non-toxic nature, small influence of processing variables
on drug release, ease of compression, and its capability to
accommodate high levels of drug loading (Ganga et al., 1992;
Taylan et al., 1996; Chattaraj and Das, 1996).
Other hydrogels such as dextran can also be used for oral
controlled release systems. Hydrogels of dextrans crosslinked
with di-isocyanate, have been applied for colon-specific drug
oi:10.1016/j.ijpharm.2006.02.049
delivery as a chemical barrier for the diffusion release of drugs
(Hovgaard and Brondsted, 1995). To date, dextrans of high
molecular weight between 5,000,000 and 40,000,000 have not
been reported as matrix controlled release system compound yet.
B110-1-2, is a native dextran of high molecular weight (more
than 5,000,000), that is mainly composed (95%) of (1-6)-linked
-d-glucose. Dextran is synthesized from sucrose by various
strains of Leuconostoc mesenteroides.
The aim of the present study was to develop a new oral con-
trolled delivery system using a natural derivative of sugar cane
(native dextran) as a main adjuvant of the matrix for a water-
soluble drug (propranolol hydrochloride). HPMC and sodium
carboxy methylcellulose (CMC) were studied as a co-adjuvant
with native dextran (DT). For optimization of the formula-
tion, central composite design was used as an experimental
design.
2. Materials and methods
2.1. Materials
Racemic propranolol hydrochloride (PPL) was obtained from
Sigma (Saint Louis, USA). High molecular weight native dex-
tran (more than 5,000,000) was obtained from the Center of
Studies of Sugar Cane, Havana, Cuba. Hydroxypropyl methyl-
cellulose (HPMC) with a viscosity grade 4000 cP (Methocel
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was measured according to the USP 25 using 20 tablets and 100
rotations during 4 min.
2.3. Dissolution testing
The in vitro dissolution tests were performed on the USP
dissolution apparatus 1 (basket) (Sotax AT7 Smart, Teknokroma,
Spain), using 900 ml of each dissolution medium (pH 1.2 or pH
6.8, prepared according to USP Propranolol Extended Release
Capsules Monograph, 2002) with a rotation speed of 100 rpm.
Amount of drug dissolved (as racemate), was measured by using
an UV–vis spectrophotometer (PC controlled Pharmacia LKB
BioChrom 4060 Spectrophotometer, Sweden) at 290 nm. Seven
diluted standard solutions of PPL, each medium (3.2, 8, 16, 24,
32, 40, 48g/ml) in a range from 10 to 150% of a theoretical
concentration of 32g/ml were prepared twice a day during 3
days from a matrix solution of 1 mg/ml for calibrate curves.
The obtained experimental data were used to determine
the required analytical parameters such as linearity (calibrate
curves: y = 19.370x− 0.001, for pH 1.2 and y = 19.187x− 0.004,
for pH 6.8 were obtained with coefficient of correlation r = 0.999
and 0.998, respectively), sensitivity, precision (repeatability:
within-day repeatability, R.S.D. = 1.5% and 1.1% for both pH,
respectively, and the intermediate precision assay: day to day
repeatability, RSD = 1.8%, 1.5% and 1.4% for 24, 32 and
40g/ml, respectively (pH 1.2) and R.S.D. = 1.5%, 1.3% and
1
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d4M) was obtained from Colorcon (Kent, England). Stearic
cid, sodium carboxy methylcellulose (CMC), polyvinylpyrroli-
one (PVP), magnesium stearate, and talc were USP 25/NFXX
uality. Spanish commercial SUMIAL RETARD, Zeneca cap-
ules (Lot. R 005) were used as a reference product. Other
hemicals and reagents were analytical grade.
.2. Matrix preparation
In the preliminary step, three different polymers (DT, HPMC,
nd CMC) and binary combinations of them were used. In all
ases the ratio between polymers (or their combinations) and
PL was constant (1:1, w/w) and a 10% PVP solution was used
s a binder solution. The drug and the excipients were sieved (80
esh). The amount of lubricants (talc and magnesium stearate)
as constant in all cases to prevent their effect on release of PPL
rom matrix. Compression was performed after granulation pro-
ess with a single punch press applying a compression force of
(preliminary work) or 12 kN (experimental design), equipped
ith a 7.9 and 9.5 mm convex punches, respectively. For the pre-
iminary work, batches of 100 tablets were prepared. Each batch
f experimental design consisted of 1000 tablets (drug content
n the tablet was 160 mg). PPL and polymers (DT and HPMC)
ere mixed for 10 min, granulated with an ethanolic solution of
etyl alcohol and passed through a 0.8 mm sieve. Granules were
ried at 45 ◦C. The dried granules (moisture content below 2%)
ere passed through a 0.8 mm sieve. The granules were then
ubricated for 2 min and press to tablet with indicated compres-
ion force (Castellanos et al., 2004).
The hardness of tablets (n = 10) was measured using a Pharma
est PTB-311 instrument (Germany). The friability of tablets.1%, respectively, for the same three concentrations (pH 6.8),
days, n = 18) and accuracy, according to Rampazoo (1990).
electivity was checked by comparing the data obtained from
ure substance and from samples spiked with excipients.
The tablets and capsules (18 replicates for each batch of
ablets and commercial SUMIAL RETARD capsules) were kept
he first hour and a half in a simulated gastric fluid at 37 ◦C, and
ubsequently in a simulated intestinal fluid at 37 ◦C (according
o the Drug Release Test 1 of USP 25 specification for Propra-
olol Hydrochloride Extended-Release Capsules) for up to 24 h.
amples were collected at suitable time intervals. Two millilitres
f aliquot was removed from each dissolution vessel and filtered
hrough a 45m filter (Millipore Corp., Bedford, MA, USA).
he same amount of fresh dissolution fluid was added to replace
he amount withdrawn. The total amount of drug present in the
ablets and capsules was calculated as the sum of the cumulative
ass of drug released at the last sample and the mass of drug
emaining (residue).
.4. Experimental design and optimization of the formula
Experimental design and optimization of formulation were
erformed using Modde 4.0 software (Umetri, Umea, Swe-
en). A central composite design was applied to the optimiza-
ion. This experimental design required 17 experiments in total
2k + 2k + 3, k is the number of variables) including three center
oints.
Three variables and five responses (according to USP 25 tol-
rances for dissolution profile for Propranolol Hydrochloride
xtended-Release Capsule) were involved in the experimental
esign. The variables and their ranges studied are summarized in
Table 1
Levels of formulation variables (central composite design)
Parameter Low value
(−1)
Central
value (0)
High value
(+1)
Ratio DT:HPMC (w/w) 1:1 4:1 7:1
Cetyl alcohol (%, w/w) 10 15 20
Ratio excipients:PPL
(%, w/w)
30 50 70
Nominal values corresponding to −1, 0 and +1 levels.
Table 1. The high and low values of each variable were defined
based on preliminary experiments. The critical responses were
t100% and t30% corresponding to the time when 100% and 30%
of drug contained in the tablets is delivered to the dissolution
medium, respectively, because this system was developed to
release drug in 24 h (t100% ∼ 24 h) and to prevent an overdose
for first minutes (t30% > 1.5 h). The other responses were in the
amount of PPL dissolved at 4, 8 and 14 h.
Table 2 shows results obtained for every formula development
according to Modde 4.0 software. The collected experimental
data were fitted by a multi linear regression (MLR) model with
which several responses can be dealt with simultaneously, to pro-
vide an overview of how all the factors affect all the responses.
The responses of the model,R2 andQ2-values were over 0.99 and
0.93 for t100% and 0.98 and 0.89 for t30%, respectively, implying
that the data fitted well with the model. Here, R2 is the fraction
of the variation of the response that can be modeled and Q2 is
the fraction of the variation of the response that can be predicted
by the model. The relationship between a response y and the
variables xi, xj. . . can be described by a polynome:
y = β0 + βixi + βjxj + βijxixj + βiix2i + βjjx2j + · · · + E
where, βj’s are coefficients to be determined and E is the overall
experimental error.
2.5. Kinetic analysis
In order to characterize the drug release mode from the opti-
mum matrix and SUMIAL RETARD capsules, the experimental
data were fitted to the Peppas, Hixon–Crowell, Higuchi and
zero-order equation (Eqs. (1)–(4), respectively) by using the
WINNONLIN program (Scientific Consulting Inc., PCNonlin,
NC, USA):
Mt/M∞ = Ktn (1)
Mt/M∞ = 1 − (1 − k1t)3 (2)
Mt/M∞ = b + k2t1/2 (3)
Mt/M∞ = a + k3t (4)
In Peppas equation (Eq. (1)), Mt/M∞ is the fraction of drug
released up to time t, K is the kinetic constant and n is the release
exponent indicative of the release mechanism (Peppas, 1985). In
Hixon–Crowell equation (Eq. (2)) (Tahara et al., 1995), Higuchi
equation (Eq. (3)) and zero-order release equation (Eq. (4)), k1,
k2 and k3 are constants. The Hixon–Crowell equation indicates
a
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Table 2
Matrix of central composite design and results
R
1
1
1
1
1
1
1
1
E , ratio
( ssolut
m lved aun order cEx:PPL DT:HPMC Ce
0 30 1:1 10
7 70 1:1 10
1 30 7:1 10
1 70 7:1 10
9 30 1:1 20
8 70 1:1 20
5 30 7:1 20
5 70 7:1 20
3 30 4:1 15
6 70 4:1 15
7 50 1:1 15
4 50 7:1 15
2 50 4:1 10
2 50 4:1 20
6 50 4:1 15
4 50 4:1 15
3 50 4:1 15
xp., number of experiments; cEx:PPL, ratio excipients:propranolol; DT:HPMC
w/w) in the tablets; t100%, time (h) when 100% of PPL is dissolved to the di
edium; t2, amount in % of PPL dissolved at 4 h; t3, amount in % of PPL disso
a Values presented are the average of 18 replicates for each batch.
b Out of the USP range.
c Inside of the USP range.n erosion-depended release mechanism. On the other hand, the
iguchi equation expresses a diffuse release mechanism. For
he analysis of the residuals, we select the relative error (Re)
xpressed by Eq. (5):
elative error (%) = |residual||experimental value| × 100 (5)
t100%a t30%a t2a t3a t4a
10 0.5b 71b 90b –b
15 2.1c 44c 73c 97b
11 0.5b 63b 82b –b
14 2.2c 40c 76c 99b
14 1.3b 49c 70c 99b
16 2.2c 46c 62c 96b
14 1.6c 49c 70c 99b
16 2.4c 43c 60c 96b
20 1.2b 54c 79c 94c
26 2.6c 39c 56c 72c
15 1.6c 45c 63c 98b
16 1.7c 43c 65c 96b
21 1.4b 52c 71c 93c
24 2.2c 45c 63c 82c
24 2.1c 48c 65c 85c
23.5 2.2c 49c 66c 86c
24 2.1c 48c 66c 86c
native dextran:hydroxypropyl methylcellulose; ce, percentage of cetyl alcohol
ion medium; t30%, time (h) when 30% of PPL is dissolved to the dissolution
t 8 h; t4, amount in % of PPL dissolved at 14 h.
2.6. Comparison of dissolution profiles
A similarity factor can be defined as:
f2 = 50 log
⎧⎨
⎩
[
1 +
(
1
n
) n∑
t=1
(Rt − Tt)2
]−0.5
× 100
⎫⎬
⎭
In the equation above f2 is the similarity factor,n is the number
of time point, Rt is the mean percent drug dissolved of e.g. the
current formulation, and Tt is the mean percent drug dissolved
of e.g. the changed composition.
The evaluation of similarity is based on the conditions of:
• a minimum of three time points,
• 12 individual values for every time point,
• not more than one mean values of >85% dissolved, and
• that the standard deviation of the mean should be less than
10% from the second to last time point.
An f2 value between 50 and 100 suggests that two dissolution
profiles are similar (Annon, 1999). In this studies experimental
data corresponding to (1.5, 4, 8, 14, 24 h) were considered.
3. Results and discussion
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from the HPMC matrix involves sequential processes of infil-
tration of medium into the matrix, hydration and swelling of the
matrix, dissolution of drug in the matrix, and the leaching of
the solubilized drug through the interstitial channels. The main
driving force for drug release would be the medium infiltration
into the tablet matrix and HPMC (4000 cP) can be used for PPL
tablet matrix (Tahara et al., 1995). Medium infiltration rate can
be adjusted by changing the polymer content or mixing various
polymers.
The HPMC:CMC:PPL ratio 0.5:0.5:1 (w/w/w) showed the
lower t100% (time when 100% of PPL dosage contained in tablets
is release) and the amount of PPL released at 1.5 h was higher.
The combination DT:HPMC showed higher values for t100%
and lower amounts of PPL were released from the tablets at
1.5 h. In this case the time required for the edges to hydrate
and reach equilibrium before erosion and the advance of solvent
front through the matrix occur is shortened. In all cases, slow
diffusion of drug is due to the increase in gel viscosity at the
periphery, which consequently leads to decrease in the rate of
formation of the swelling front into the matrix.
Previously it has been demonstrated that the increase of
gel viscosity is synergistic when mixtures of these polymers
are used. The ratio of the total gum to the drug and the ratio
between hydrogels in the tablets are very important (Harris and
Sellassie, 1989). In the following experiments, only combina-
tions of dextran and HPMC were used. The values for t
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l.1. Development of the formula
Application of CMC polymer alone exhibited an increase in
he release rate of PPL for the first few hours (Fig. 1). This
ay be attributed to the increase in the erosion rate of the CMC
olymer. Later, the polymer swelling (i.e. an increase in the dif-
usional path length) retards the rate of release. When dextran
f high molecular weight with a lot of ramifications was used,
decrease in the release rate of drug was observed. This may
e attributed to an increase in diffusional path length for the
rug, which in turn may be due to the slower erosion rate of
he rubbery layer and faster advancement of the swelling of the
lassy polymer. HPMC also decreases the release rate of PPL.
ts mechanism is well known as a swelling controlled release
ystem (Colombo et al., 2000). Release of soluble drugs as PPL
ig. 1. Dissolution profiles for propranolol hydrochloride obtained in prelimi-
ary work.100%
ncreased dramatically when PVP was replaced by cetyl alco-
ol and the amount of it was increased up to 15% (w/w) in the
atrix system. On the other hand, inclusion of stearic acid did
ot improve dissolution of PPL.
Fig. 2 represents the dissolution profiles all 17 trials gener-
ted from central composite design. The response surface plots
ormed by plotting the values for t30% and t100% as a function
f the most important variables are shown in Fig. 3. In Fig. 3,
he optimum condition obtained by the model can be seen. The
ptimum DT:HPMC ratio of 4:1 (w/w) gave t100% equal to 24 h.
ith the tablet formulations composing of matrix excipient and
PL at a ratio ranging from 40:60 to 70:30 (w/w), the values for
100% were satisfactory (around 24 h). However, the respective
alues for t30% increased as a ratio of matrix excipient and PPL
as ranging from 40:60 to 70:30 (w/w), thus showing that the
arly drug release was demanded and the initial dose required for
harmacological effect could be not sufficient. The sustained-
elease matrix tablets with good properties were obtained with a
extran:HPMC ratio of 4:1 (w/w), with a matrix excipient:PPL
atio of 60:40 (w/w) and with a cetyl alcohol amount of 15%
w/w). Ratio hydrophilic polymers:PPL 60:40 (w/w) is more
obustness for any manufactured variability than 50:50 (w/w),
ecause the central point of the design is near to the lowest
esired area (Fig. 3). Under the optimal conditions, the mean
alue of hardness was 106 ± 3 N and the friability was less than
% (0.2%).
Cetyl alcohol (ce in Fig. 4) has a significant positive effect
n both responses in the range studies. This may be because the
ydrophobic polymer prevents the fast release of PPL for the
rst few hours, meanwhile an increase in the diffusional path
ength of the drug, because the hydrophilic polymers swelling
Fig. 2. Dissolution profiles of all 17 trials generated from central composite design.
(DT and HPMC) retard the rate of release. An interaction of
cetyl alcohol and ratio hydrophilic polymers:PPL was observed
for t30%. If a prolonged release rate is desired on this period,
ratio of hydrophilic to cetyl alcohol can be increased, resulting
in a decreased interspace volume after erosion of cetyl alco-
hol. Different to other product such as lactose (Tahara et al.,
1995), cetyl alcohol as hydrophobic polymer could be increased.
The viscosity and texture of the gel layer and some modifica-
tions of interaction polymer–polymer and polymer–solvent are
present.
Fig. 5 shows dissolution profiles for optimum formula
(tablets), which come from previous experiments and for SUM-
IAL RETARD capsules. The value for relative standard devia-
tion (CV) was less than 6% for all points measured (n = 18). The
dissolution profiles were in the range of tolerance established in
USP 25 for Propranolol Hydrochloride Extended-Release Cap-
sules, as shown in Table 3.
Three release mechanisms (Higuchi, Hixon–Crowell and
zero order release equation) were applied to study the disso-
lution data of the optimum formulation and SUMIAL RETARD
capsules. The parameters and correlation coefficient of each
equation as well as the values for non-linear equation (Peppas)
are shown in Table 4. The dissolution data best fit the Higuchi
and Hixon–Crowell equation. This indicates that the dissolution
is both diffusion and erosion dependent. On the other hand, the
values obtained from Peppas model indicate that the main mech-
Fig. 3. Response surface plot showing the t30% and t100% as a function of corre-
lation DT:HPMC, ratio Exc:PPL and percentage of cetyl alcohol in the formula.
anism is diffusion (n = 0.48) for the first part of the release curve
(up to 60% of drug dissolve).
Plot of experimental values, Higuchi and Hixon–Crowell
models for release of PPL from tablets is shown in Fig. 6. Both
curves (diffusion and erosion) are similar to experimental values
(Fig. 6A) and when experimental values versus predicted val-
ues by the models are plotted (Fig. 6B), the regression lines for
each model almost superpose indicating that both mechanisms
are predictive. However, the analysis of relative error (Table 4)
indicate that diffusional model have been more predictive with
better fit in the early parts of the release curve (up to 4 h) but
later that is not so clear (from 4 up to 24 h) because values for Re
are similar and both mechanisms are operative. The erosion and
dissolution of HPMC and cetyl alcohol explains this combina-
tion. According to the literature, a drug release from hydrophilic
matrix system is governed sequentially by the following pro-
cesses: (1) hydration or swelling of the matrix which results
in the formation of a gel; (2) dissolution of the drug into that
hydrated matrix/gel; (3) diffusion of the drug molecules through
Fig. 4. Regression coefficient plot for the t30% and t100%: DT, ratio dex-
tran:HPMC (w/w); cEx, ratio excipients:propranolol (w/w); ce, percentage of
cetyl alcohol (w/w) in the tablets.
that hydrated matrix; and finally (4) surface erosion and/or dis-
solution of the formed gel–matrix (Talukdar and Kinget, 1997).
3.2. Similarity
On several occasions dissolution profiles have to be com-
pared for similarity, e.g. after scale-up or changes in composition
Fig. 5. Dissolution profiles of PPL for optimum formula (sustained-release
tablets) and for SUMIAL RETARD sustained-release capsule.
Table 3
The percentage of the labeled amount of hydrochloride propranolol dissolved at the times specified conform to Acceptance Table 1 of Test 1 for Propranolol
Hydrochloride Extended-Release Capsule USP 25 tolerance
Time (h) Amount dissolved (%) Similarity factor
USP 25 tolerances Tablets (optimum) Capsule SUMIAL RETARD
1.5 <30 21.3 ± 4.4a 18.9 ± 4.1a
4 35–60 43.1 ± 4.2a 40.2 ± 3.1a (f2)
8 55–80 60.1 ± 3.1a 65.2 ± 2.8a 69.6
14 70–95 79.3 ± 2.8a 84.9 ± 2.6a
24 81–110 97.6 ± 2.9a 99.1 ± 2.1a
Amounts dissolved of propranolol hydrochloride are expressed as average values of 12 samples.
a Relative standard deviation obtained for 12 samples.
Table 4
Parameters and correlation coefficient obtained from kinetic equations for the matrix tablets (optimum) and SUMIAL RETARD capsule
Parameter Higuchi Hixon–Crowell Zero order Peppas
Tablets (optimum)
k 0.208 0.035 0.049 22.828
r 0.999 0.997 0.943 0.999
n – – – 0.484
Capsule (SUMIAL RETARD)
k 0.215 0.029 0.051 22.914
r 0.998 0.987 0.961 0.999
n – – – 0.501
TIME (h) Percent dissolved HIX. HIG. HIX RES HIG RES HIX-Re HIG-Re
Predicted values for Higuchi and Hixon–Crowell models
1.5 21.30 14.55 25.14 6.75 −3.84 31.68 18.03
4 43.10 35.54 41.05 7.56 2.05 17.53 4.75
8 60.10 61.48 58.06 −1.38 2.04 2.29 3.40
14 79.30 85.66 76.80 −6.36 2.50 8.03 3.15
24 97.60 99.39 100.56 −1.79 −2.96 1.83 3.03
Residuals and relative error (Re) (for tablets). All values are expressed as average values for 18 samples. k, kinetic constant; r, coefficient of correlation; n, release
exponent; HIX., predicted values Hixon–Crowell model; HIG., predicted values Higuchi model; HIX RES, residuals Hixon–Crowell model; HIG RES, residuals
Higuchi model; HIX-Re, relative error Hixon–Crowell model; HIG-Re, relative error Higuchi model.
Fig. 6. (A) Plot of experimental values, Higuchi and Hixon–Crowell models for release of PPL from tablets. (B) Plot of experimental vs. predicted by the models.
and/or manufacturing process. The similarity of the profiles may
be compared by model-independent or model-dependent meth-
ods, e.g. linear regression of the percentage dissolved at specified
time points, by statistical comparison of the parameters of the
Weibull function or by calculating a similarity factor. We calcu-
lated this last one and the value obtained for SUMIAL RETARD
capsule and optimum tablet (see Table 3) established that dis-
solution profiles are similar even when different polymers were
used and different manufacturing processes were performed.
4. Conclusions
The optimal formula was obtained through a central com-
posite experimental design. Under optimal ratio of matrix com-
pound and drug (60:40, w/w), optimal ratio of native dextran
and HPMC (4:1, w/w) and 15% of cetyl alcohol, the new sys-
tem presented is suitable for controlled release of PPL for 24 h
and it fulfil the USP 25 Drug Release Test 1 for Extended-
Released Hydrochloride propranolol capsule. Similarity fac-
tor f2 = 69.6 obtained between tablets and SUMIAL RETARD
capsule, suggests that the two prolonged release oral dosage
forms dissolution profiles are similar. Higuchi (diffusion) and
Hixon–Crowell (erosion) kinetic profiles were achieved, and
consequently, codependent diffusion/erosion mechanism is sug-
gested as a main release mechanism of PPL from the present
t
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